Despite its many benefits including patient convenience and cost reduction, point-of-care (POC) diagnostics has not achieved the commercial potential that many expected. That will change in the coming years, according to Yole Développement (Lyon, France), which predicts that the sector will reach $38 billion by 2017, representing 16% of the in vitro diagnostics market. That is welcome news for patients and payers. Tagging Options Domain:  All Sites Keywords:  medical Polymers read more

View article:
Plastics have material advantage in growing point-of-care diagnostics market